As single-stock leveraged ETFs continue to proliferate, Defiance ETFs last week added a 2X Moderna Inc (NASDAQ:MRNA)-linked fund, the Defiance Daily Target 2X Long MRNA ETF (NYSE:MRNX), targeting traders looking for magnified short-term exposure to the biotech giant.

The new ETF aims to deliver two times or 200 percent daily percentage movements of shares for Moderna, a biotechnology company that has gained prominence for its mRNA technology and vaccine capacity. The fund targets short-term tactical positioning rather than long-term investment exposure, reflecting the typical use case for leveraged ETFs.

According to the firm, MRNX enables investors to gain a liquid and exchange-traded vehicle to bet on their bullish, short-term views on Moderna stock, bypassing any direct utilization of derivatives or margin accounts. The fund resets daily and, like all other day leveraged ETFs, is not intended to track twice the stock’s performance over period-long holding periods.

New ETF Offers Amplified MRNA Exposure

Moderna remains one of Wall Street’s most closely watched names within biotechnology, with its work in mRNA-based therapeutics and vaccines. It gained global recognition during the COVID-19 pandemic for its mRNA vaccine, and continued to expand research in infectious diseases while also pursuing other areas of unmet medical needs. Its technology platform focuses on using messenger RNA to instruct cells to produce proteins that can help prevent or treat disease.

The launch marks continued growth in the single-stock ETF segment, where issuers are increasingly offering leveraged and inverse products linked to individual companies versus broad indexes. These strategies have gained traction among active traders seeking short-term opportunities linked to earnings cycles, sector momentum, or company-specific catalysts.

Defiance ETFs said the fund is intended primarily for sophisticated investors who actively monitor positions and understand the risks associated with leveraged products, including potential volatility and performance divergence over extended holding periods.

With MRNX, the company further extends its suite of leveraged ETFs focused on companies perceived as leaders in emerging technologies, with a specific concentration on biotechnology and life sciences.

Image: Shutterstock

• No comments yet. Be the first to comment!